descriptionElusys delivers first shipment of ANTHIM®, its treatment for Inhalational Anthrax, to U.S. Government Strategic National Stockpile

descriptionElusys Receives $16.35 Million for Delivery of ANTHIM® to U.S. Government

descriptionElusys Therapeutics Announces Publication of Data Establishing the Adult Human Dose for its Inhalational Anthrax Antitoxin ANTHIM® (Obiltoxaximab) Injection

descriptionElusys Therapeutics Announces Publication of Results from Five Clinical Trials with its Inhalational Anthrax Antitoxin ANTHIM® (Obiltoxaximab) Injection

descriptionElusys Therapeutics Announces that Manuscripts for its Anthrax Antitoxin, ANTHIM® (Obiltoxaximab) Injection, have been Accepted for Publication

descriptionElusys Therapeutics Receives FDA Approval for ANTHIM® (Obiltoxaximab) Injection for the Treatment and Prophylaxis of Inhalational Anthrax

descriptionElusys Therapeutics Receives First Delivery Order from U.S. Government for ANTHIM® (Obiltoxaximab) for Treatment of Inhalational Anthrax

descriptionElusys Awarded Additional $16 Million Under Existing U.S. Government Contract to Complete Development of Lyophilized Form of ANTHIM® (Obiltoxaximab) for Treatment of Inhalational Anthrax

descriptionU.S. Food and Drug Administration Accepts Biologics License Application for ANTHIM (Obiltoxaximab)

descriptionElusys Reports Efficacy of its Anthrax Anti-Toxin In Post-Exposure Prophylaxis In Animal Studies

descriptionElusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program

descriptionElusys Completes Commercial Manufacturing Process Validation for Anthrax Antitoxin ETI-204

descriptionElusys Receives Notice of Allowance from U.S. Patent Office for Methods of Preventing or Treating Anthrax with ETI-204, an Anti-Anthrax Antibody, via Intramuscular Injection

descriptionElusys Completes Enrollment In Three Phase 3 Safety Studies Of Its Anthrax Anti-toxin, ETI-204, In Adult Volunteers

descriptionElusys Reports Its Anti-toxin Achieved 100% Survival Rate Following Anthrax Challenge In Pre-treatment Animal Study

descriptionElusys Therapeutics presents efficacy results and other key findings on ETI-204 Anthrax anti-toxin

descriptionMedia advisory-Elusys Therapeutics to present results on ETI-204 Anthrax anti-toxin

descriptionElusys releases new data on Anthrax anti-toxin administered via intramuscular injection from three recent animal studies

descriptionAlliance for biosecurity elects Chief Executive Officers of Bavarian Nordic and Elusys Therapeutics as new co-chairs

descriptionElusys awarded additional $14.5 million under existing U.S. government contracts supporting expanded human safety studies of ETI-204 for treatment of inhalational anthrax

descriptionElusys picks up $50.2M BARDA funds to advance anthrax antitoxin

descriptionElusys awarded additional $50.2 million under an existing U.S. government contract to support final stages of development of ETI-204, for treatment of inhalational Anthrax

descriptionElusys initiates third clinical safety study of Anthim, a new anthrax treatment; company successfully completes manufacturing at commercial scale

descriptionElusys awarded $68 million contract to develop Anthim for intramuscular pre- and post-exposure prophylaxis of anthrax infection

descriptionRegulatory Affairs Executive, Greg Torre, PhD, Esq, Joins Elusys Therapeutics Management Team

descriptionElusys Awarded Additional $40.6 Million Under Exisiting US Government Contract To Fund Advanced Development Of Anthim, A New Treatment For Anthrax

descriptionElusys Therapeutics and Lonza Extend Manufacturing Agreement For Anthim, a New Anthrax Treatment In Late-Stage Development

descriptionElusys Receives Contract for up to $143 Million from the US Federal Government to Fund Advanced Development of Anthim®, a New Treatment for Anthrax

descriptionElusys Presents Data from Anthim® Anthrax Anti-toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day

descriptionElusys Therapeutics and Lonza Enter Into Manufacturing Agreement

descriptionElusys’ Anthim™ Dramatically Improves Survival of Animals Treated After Active Anthrax Infection